The Precision Medicine Gap: When Knowing the Target Is Not Enough

Article

Precision oncology has traditionally been framed as a scientific challenge: identify the molecular driver, develop a therapy against it, and improve outcomes. But what happens when we already have the test, understand the target, and have an effective therapy—yet the patient still doesn't receive it? A 2026 study published in the Journal of Managed Care & Specialty Pharmacy examined this problem in metastatic non-small cell lung cancer (NSCLC). Researchers modeled more than 92,000 newly diagnosed U.S. patients and estimated that approximately 53% would harbor an actionable molecular alteration with an available first-line targeted therapy. Under optimal precision-medicine practice, nearly 47,000 patients would be identified and receive matched therapy. Under observed practice, only about 28,000 would. The modeled consequence: approximately 20,900 life-years lost each year. This is a simulation, not a directly observed clinical outcome, so the exact number should be interpreted cautiously. But the larger message is difficult to ignore. Precision medicine depends on an entire chain: Test the patient → identify the molecular driver → interpret the result → select the matched therapy → get it to the patient. A failure anywhere in that chain can separate an effective therapy from the patient who might benefit. And simply ordering more molecular tests isn't enough. The information generated by those tests must be translated into clinical action. As the number of actionable biomarkers and targeted therapies grows, this implementation gap becomes increasingly important. The next major gains in precision oncology may not come exclusively from discovering another target or developing another drug. Some may come from ensuring that what we already know is actually used. The study raises a fundamental question: What is the value of precision medicine if precision is lost somewhere between the laboratory and the patient? Reference: Migliaccio-Walle K, et al. Clinical harm from failure to deploy personalized medicine for patients with metastatic non-small cell lung cancer. Journal of Managed Care & Specialty Pharmacy. 2026;32(8):1029–1040.